Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

被引:77
作者
Kemp, Troy J. [1 ]
Garcia-Pineres, Alfonso [1 ]
Falk, Roni T. [2 ]
Poncelet, Sylviane [3 ]
Dessy, Francis [3 ]
Giannini, Sandra L. [3 ]
Rodriguez, Ana Cecilia [4 ]
Porras, Carolina [4 ]
Herrero, Rolando [4 ]
Hildesheim, Allan [2 ]
Pinto, Ligia A. [1 ]
机构
[1] NCI Frederick, SAIC Frederick Inc, HPV Immunol Lab, Frederick, MD 21702 USA
[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[3] GlaxoSmithKline Biol, Res & Dev, B-1330 Rixensart, Belgium
[4] Proyecto Epidemiol Guanacaste, San Jose, Costa Rica
关键词
human papillomavirus; neutralization assay; cervical secretions;
D O I
10.1016/j.vaccine.2008.04.074
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ideal methods to monitor HPV neutralizing antibodies induced by vaccination have not been established yet. Here, we evaluated systemic and cervical antibody levels induced by HPV16/18 AS04-adjuvanted vaccine (GlaxoSmithKline Biologicals) using a secreted alkaline phosphatase neutralization assay (SEAP-NA) and enzyme-linked immunosorbent assay (ELISA). Serum and cervical secretions from 50 vaccinated women were used to assess (1) overall assay reproducibility; (2) inter-assay and inter-specimen correlation; (3) correlations between month I and month 12 titers. Strong correlations between SEAP-NA and ELISA were observed (serum anti-HPV16/18, rho = 0.91/0.85; cervix anti-HPV16/18, rho = 0.84/0.89). Systemic and cervical antibody measures also correlated well (rho range: 0.64-0.75); except at mid-cycle (rho range: 0.28-0.65). Correlations between antibody levels at 1 and 12 months following the start of vaccination were poor (rho range: 0.16-0.38). In conclusion, HPV16/18 VLP-based ELISA is a reliable and valid method to monitor anti-HPV16/18 neutralizing potential for the first year following vaccination; however, additional studies will be required to better define the effects of the time on cycle and patterns of antibody response over time following vaccination. (C) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3608 / 3616
页数:9
相关论文
共 31 条
  • [1] [Anonymous], 1989, SELECTED PAPERS C R
  • [2] PREVALENCE OF HUMAN PAPILLOMAVIRUS IN CERVICAL-CANCER - A WORLDWIDE PERSPECTIVE
    BOSCH, FX
    MANOS, MM
    MUNOZ, N
    SHERMAN, M
    JANSEN, AM
    PETO, J
    SCHIFFMAN, MH
    MORENO, V
    KURMAN, R
    SHAH, KV
    ALIHONOU, E
    BAYO, S
    MOKHTAR, HC
    CHICAREON, S
    DAUDT, A
    DELOSRIOS, E
    GHADIRIAN, P
    KITINYA, JN
    KOULIBALY, M
    NGELANGEL, C
    TINTORE, LMP
    RIOSDALENZ, JL
    SARJADI
    SCHNEIDER, A
    TAFUR, L
    TEYSSIE, AR
    ROLON, PA
    TORROELLA, M
    TAPIA, AV
    WABINGA, HR
    ZATONSKI, W
    SYLLA, B
    VIZCAINO, P
    MAGNIN, D
    KALDOR, J
    GREER, C
    WHEELER, C
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1995, 87 (11): : 796 - 802
  • [3] IMMUNIZATION WITH VIRUS-LIKE PARTICLES FROM COTTONTAIL RABBIT PAPILLOMAVIRUS (CRPV) CAN PROTECT AGAINST EXPERIMENTAL CRPV INFECTION
    BREITBURD, F
    KIRNBAUER, R
    HUBBERT, NL
    NONNENMACHER, B
    TRINDINHDESMARQUET, C
    ORTH, G
    SCHILLER, JT
    LOWY, DR
    [J]. JOURNAL OF VIROLOGY, 1995, 69 (06) : 3959 - 3963
  • [4] Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors:: Implications for screening and prevention
    Castellsagué, X
    Díaz, M
    de Sanjosé, S
    Muñoz, N
    Herrero, R
    Franceschi, S
    Peeling, RW
    Ashley, R
    Smith, JS
    Snijders, PJF
    Meijer, CJLM
    Bosch, FX
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05): : 303 - 315
  • [5] Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions
    Castle, PE
    Rodriguez, AC
    Bowman, FP
    Herrero, R
    Schiffman, M
    Bratti, MC
    Morera, LA
    Schust, D
    Crowley-Nowick, P
    Hildesheim, A
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2004, 11 (02) : 399 - 405
  • [6] Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: Implication for optimal age of human papillomavirus vaccination
    Chen, Chih-Jung
    Viscidi, Raphael P.
    Chuang, Chih-Hsien
    Huang, Yhu-Chering
    Chiu, Cheng-Hsun
    Lin, Tzou-Yien
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2007, 38 (02) : 126 - 130
  • [7] Carcinogenicity of human papillomaviruses
    Cogliano, V
    Baan, R
    Straif, K
    Grosse, Y
    Secretan, B
    El Ghissassi, F
    [J]. LANCET ONCOLOGY, 2005, 6 (04) : 204 - 204
  • [8] Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18
    Dias, D
    Van Doren, J
    Schlottmann, S
    Kelly, S
    Puchalski, D
    Ruiz, W
    Boerckel, P
    Kessler, J
    Antonello, JM
    Green, T
    Brown, M
    Smith, J
    Chirmule, N
    Barr, E
    Jansen, KU
    Esser, MT
    [J]. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (08) : 959 - 969
  • [9] Gail MH, 1996, CANCER EPIDEM BIOMAR, V5, P835
  • [10] Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
    Garland, Suzanne M.
    Hernandez-Avila, Mauricio
    Wheeler, Cosette M.
    Perez, Gonzalo
    Harper, Diane M.
    Leodolter, Sepp
    Tang, Grace W. K.
    Ferris, Daron G.
    Steben, Marc
    Bryan, Janine
    Taddeo, Frank J.
    Railkar, Radha
    Esser, Mark T.
    Sings, Heather L.
    Nelson, Micki
    Boslego, John
    Sattler, Carlos
    Barr, Eliav
    Koutsky, Laura A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (19) : 1928 - 1943